Keywords: QrXPharma, MoxDuo IR, Pain, Actavis, US opioid market

QRxPharma value assed as Actavis deal finalized

Article | 29 March 2012

Print This

Australian company QRxPharma (ASX: QRX) is moving rapidly towards the commercial phase for its lead product, MoxDuo IR, an immediate ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in